These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26139550)

  • 21. Influence of Tyrosine Kinase Inhibitor, Nilotinib, on Delayed Healing of Bare-Metal Stents in Superficial Femoral Arteries: Insights From Angioscopic Findings.
    Kuwasaki S; Koga S; Akashi R; Ikeda S; Kawano H; Maemura K
    JACC Cardiovasc Interv; 2019 May; 12(10):e85-e86. PubMed ID: 31029618
    [No Abstract]   [Full Text] [Related]  

  • 22. [Nilotinib as a second-line treatment for chronic myeloid leukemia].
    Yamauchi T; Ueda T
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):911-5. PubMed ID: 21677481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up.
    Aghel N; Lipton JH; Atenafu EG; Kim DDH; Delgado DH
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):870-878.e1. PubMed ID: 28803825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ultrasound arterial anomalies in patients exposed to nilotinib therapy for chronic myeloid leukemia.
    Sarlon-Bartoli G; Michel Q; Sarlon E; Carcopino-Tusoli M; Suchon P; Soler R; Bartoli MA; Brunet D; Morange P; Charbonnier A
    J Med Vasc; 2021 Apr; 46(2):66-71. PubMed ID: 33752848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Tyrosine kinase inhibitor-associated cardiovascular adverse events in chronic myeloid leukemia].
    Miyazaki S
    Rinsho Ketsueki; 2021; 62(8):1024-1028. PubMed ID: 34497188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: who's afraid of the big bad wolf?
    Breccia M; Efficace F; Alimena G
    Leuk Res; 2012 Jul; 36(7):813-4. PubMed ID: 22483067
    [No Abstract]   [Full Text] [Related]  

  • 27. Intracranial stenting for nilotinib treatment-associated cerebrovascular stenosis in chronic myeloid leukemia.
    Ozaki T; Nakamura H; Izutsu N; Masaie H; Ishikawa J; Kinoshita M
    Interv Neuroradiol; 2017 Oct; 23(5):527-530. PubMed ID: 28583043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical cardiac safety profile of nilotinib.
    Kim TD; le Coutre P; Schwarz M; Grille P; Levitin M; Fateh-Moghadam S; Giles FJ; Dörken B; Haverkamp W; Köhncke C
    Haematologica; 2012 Jun; 97(6):883-9. PubMed ID: 22271904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
    Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
    Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusion.
    Maurizot A; Beressi JP; Manéglier B; de la Marre NH; Spentchian M; Soury P; Solvet-Sebire P; Collet-Gaudillat C; Baud JM; Livarek B; Guilhot F; Rousselot P
    Blood Cancer J; 2014 Sep; 4(9):e247. PubMed ID: 25238138
    [No Abstract]   [Full Text] [Related]  

  • 31. Nilotinib-induced liver injury: A case report.
    Tan Y; Ye Y; Zhou X
    Medicine (Baltimore); 2020 Sep; 99(36):e22061. PubMed ID: 32899072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Leg ulcers occurring under tyrosine kinase inhibitor therapy (sunitinib, nilotinib)].
    Roger A; Sigal ML; Bagan P; Sin C; Bilan P; Dakhil B; Fargeas C; Couffinhal JC; Mahé E
    Ann Dermatol Venereol; 2017 Jan; 144(1):49-54. PubMed ID: 27527566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.
    Lin J; Makenbaeva D; Lingohr-Smith M; Bilmes R
    J Med Econ; 2017 Jul; 20(7):687-691. PubMed ID: 28287043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal Response in a Patient With CML Expressing
    Manzella L; Tirrò E; Vitale SR; Puma A; Consoli ML; Tambè L; Pennisi MS; DI Gregorio S; Romano C; Tomarchio C; DI Raimondo F; Stagno F
    In Vivo; 2020; 34(3):1481-1486. PubMed ID: 32354950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis.
    Chai-Adisaksopha C; Lam W; Hillis C
    Leuk Lymphoma; 2016; 57(6):1300-10. PubMed ID: 26373533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia].
    Dou XL; Wang SS; Fang JL; Yu L; Ren X; Huang XJ; Jiang Q
    Zhonghua Nei Ke Za Zhi; 2018 Sep; 57(9):649-655. PubMed ID: 30180449
    [No Abstract]   [Full Text] [Related]  

  • 37. Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors.
    Jabbour E; Cortes J; Kantarjian H
    Cancer; 2011 Mar; 117(5):897-906. PubMed ID: 20945321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
    Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
    Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia.
    Kim TD; Schwarz M; Nogai H; Grille P; Westermann J; Plöckinger U; Braun D; Schweizer U; Arnold R; Dörken B; le Coutre P
    Thyroid; 2010 Nov; 20(11):1209-14. PubMed ID: 20929406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.